APRI - Apricus Biosciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.74
+0.00 (+0.01%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close1.74
Open1.72
Bid1.69 x 100
Ask1.95 x 2900
Day's Range1.69 - 1.77
52 Week Range0.86 - 4.07
Volume206,998
Avg. Volume204,848
Market Cap26.475M
Beta-0.66
PE Ratio (TTM)7.07
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Should You Buy Apricus Biosciences Inc (APRI) Now?
    Simply Wall St.22 days ago

    Should You Buy Apricus Biosciences Inc (APRI) Now?

    Apricus Biosciences Inc (NASDAQ:APRI), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMT

    Q3 2017 Apricus Biosciences Inc Earnings Call

  • Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?
    Simply Wall St.2 months ago

    Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?

    For Apricus Biosciences Inc’s (NASDAQ:APRI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT

    Q2 2017 Apricus Biosciences Inc Earnings Call

  • Capital Cube4 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Associated Press4 months ago

    Apricus reports 2Q loss

    The San Diego-based company said it had a loss of 13 cents per share. Losses, adjusted to account for discontinued operations, came to 15 cents per share. In the final minutes of trading on Wednesday, ...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT

    Q1 2017 Apricus Biosciences Inc Earnings Call

  • Associated Press7 months ago

    Apricus posts 1Q profit

    On a per-share basis, the San Diego-based company said it had net income of $1.04. Losses, adjusted to account for discontinued operations, were 44 cents per share. In the final minutes of trading on Thursday, ...

  • Capital Cube8 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube8 months ago

    ETFs with exposure to Apricus Biosciences, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube9 months ago

    Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Apricus Biosciences, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Apricus Biosciences, Inc. – VIVUS, Inc., Pfizer Inc., Bioanalytical Systems, Inc., Abbott Laboratories, Eli Lilly and Company, Ligand Pharmaceuticals Incorporated and Novartis AG Sponsored ADR (VVUS-US, PFE-US, BASI-US, ... Read more (Read more...)

  • Associated Press9 months ago

    Apricus reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 4 cents. The drugmaker posted revenue of $400,000 in the period. For the year, the company reported that its loss narrowed to $7.4 ...

  • Investopedia9 months ago

    Apricus Biosciences Sells ED Therapy Rights

    Apricus will receive $12.7 million from the sale of its erectile dysfunction therapy Vitaros to Ferring.

  • 24/7 Wall St.11 months ago

    Thursday’s Top Biopharma Movers

    Not that many biotech and pharma companies were on the move Thursday, just one day before the inauguration. However, a few of the smaller caps made splash.

  • Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
    Zacks11 months ago

    Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

    Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

  • 24/7 Wall St.11 months ago

    How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double

    The biotechs and emerging pharma have been under pressure from politicians attacking drug prices. That doesn't mean that there are not some big winners out there.

  • 24/7 Wall St.11 months ago

    Wednesday’s Top Biopharma Winners

    Trump said last week that companies in the health care sector are “getting away with murder,” and that something had to change. The sector has pulled back slightly since then, but there are still companies ...

  • Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
    Zacks11 months ago

    Apricus Launches Vitaros in Lebanon for Erectile Dysfunction

    Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.

  • Capital Cubelast year

    ETFs with exposure to Apricus Biosciences, Inc. : December 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Apricus Biosciences, Inc. Here are 5 ETFs with the largest exposure to APRI-US. Comparing the performance and risk of Apricus Biosciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)